E2 ModerateModerate confidencePEM not requiredCross-SectionalPeer-reviewedMachine draft
Standard · 3 min
Comprehensively understanding fatigue in patients with myeloproliferative neoplasms.
Scherber, Robyn M, Kosiorek, Heidi E, Senyak, Zhenya et al. · Cancer · 2016 · DOI
Quick Summary
This study surveyed nearly 1,800 people with myeloproliferative neoplasms (blood cancers) about their fatigue. Researchers found that fatigue was very common and severe, and it was worse in people who were overweight, used alcohol or tobacco, didn't exercise, or had other conditions like fibromyalgia or chronic fatigue syndrome. The study also found that many people with these blood cancers had depression, which was linked to their fatigue.
Why It Matters
This study is relevant to ME/CFS research because it comprehensively examines fatigue etiology in a large patient cohort and identifies multiple overlapping conditions—including chronic fatigue syndrome itself—that worsen fatigue outcomes. The strong association between fatigue severity and depression, combined with identification of modifiable lifestyle factors, suggests that multifactorial approaches to fatigue management may benefit both MPN patients and those with ME/CFS who experience similar symptom burdens.
Observed Findings
Higher BMI, current alcohol use, and current tobacco use were significantly associated with greater fatigue severity.
Exercising at least once per week was associated with lower fatigue compared to no exercise.
Fibromyalgia, restless leg syndrome, chronic fatigue syndrome, diabetes mellitus, and chronic kidney disease were all significantly associated with increased fatigue.
Approximately 25% of respondents met depression screening criteria (PHQ score >2).
Higher fatigue scores were strongly associated with higher depression screening scores (P<0.0001).
Inferred Conclusions
Fatigue in patients with myeloproliferative neoplasms is multifactorial, involving disease-specific, lifestyle, medical comorbidity, and psychiatric components.
Modifiable risk factors (exercise, weight, substance use) and medication-related factors should be systematically assessed and addressed in fatigue management.
Patients with MPNs have elevated rates of depression and mood disturbances compared to the general population, suggesting psychological screening and intervention should be integrated into fatigue management.
Remaining Questions
Does treating the identified modifiable factors (e.g., increasing exercise, reducing alcohol use, optimizing weight) actually reduce fatigue in MPN patients?
What This Study Does Not Prove
This study does not prove causation—only association. For example, finding that antidepressant use correlates with worse fatigue does not mean the medications cause fatigue; it may reflect that sicker patients are more likely to be prescribed these drugs. The cross-sectional design cannot establish temporal relationships, and findings from MPN patients may not directly apply to ME/CFS populations, which have distinct pathophysiology.
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →
What is the temporal relationship between depression and fatigue—does depression cause fatigue, does fatigue cause depression, or do both arise from shared biological mechanisms?
How do findings in MPN-associated fatigue apply to ME/CFS, and are there distinct or overlapping pathogenic pathways in the two conditions?
Do the medications associated with worse fatigue (antidepressants, antihistamines, opioids) actually cause or worsen fatigue, or is their association purely confounded by disease severity?